The treatment of NSCLC has recently been improved by development of immune checkpoint inhibitors (ICIs), which target inhibitor pathways such as programmed death 1 (PD1)/programmed death-ligands 1 (PDL1), thus blocking the immune responses of tumor-infiltrating lymphocytes, allowing proliferation of tumor cells [2]. This evidence concerns the gene CD274 and neoplasm.